The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an AcylCoA:Cholesterol Acyl Transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers
✍ Scribed by R. W. Peck; R. Wiggs; J. Posner
- Publisher
- Springer
- Year
- 1995
- Tongue
- English
- Weight
- 657 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
✦ Synopsis
2 dimethylpropyl)
phenyl)ethyl)phenyl)urea) is an inhibitor of human microsomal AcylCoA: Cholesterol acyltransferase (ACAT) with an ICs0 of 10.2 rig' m1-1 (23 nM). It is poorly absorbed but 5 mg. kg-1-daycompletely abolishes the rise in plasma cholesterol in cholesterol-fed rats.
In this study, twelve healthy, male volunteers received single, oral doses of 25, 50, 100, 200, 400 and 800 mg of 447C88 (n = 8) or placebo (n = 4) with food in a double-blind study with at least a week between occasions. The 400 mg dose was repeated after an overnight fast. Subsequently, fourteen different volunteers received a single 200 mg dose of 447C88 (n = 8) or placebo (n = 6) with food and, a week later, the same dose twice daily for 10 days; all doses were given with food.
All doses were well tolerated with no significant changes in vital signs, full blood counts or plasma biochemical profiles. Plasma concentrations of 447C88 were unquantifiable after the fasting dose and low after all other doses. Mean Cma x and AUC were 1.8 ng-m1-1 and 9.0 ng. ml 1. h after 200 mg rising to 5.4 ng m1-1 and 23.8 ng ml i. h respectively after 800 mg; t~/2 was 1.3 to 5.2 h. After 10 days dosing, plasma 447C88 concentrations were higher in the evening than the morning probably due to administration of the evening dose with more food. There were no significant changes in plasma triglcerides or total, LDL-or HDL-cholesterol after dosing with 447C88.